Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Sodium Thiosulfate in Treating Patients With High-Grade Glioma


Phase II Clinical Trial Of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized To Treatment With Or Without Delayed Intravenous Sodium Thiosulfate As A Potential Chemoprotectant Against Severe Thrombocytopenia


Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and etoposide phosphate, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. Chemoprotective drugs, such as sodium thiosulfate, may protect blood platelets from the side effects of chemotherapy.


This randomized phase II trial is studying combination chemotherapy and sodium thiosulfate to see how well they work compared to combination chemotherapy alone in treating patients with high-grade glioma.

Study Status: Recruiting

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: etoposide phosphate
Drug: sodium thiosulfate
Phase 2

Verified by Oregon Health and Science University June, 2009

Sponsored by: Oregon Health and Science University
Information provided by: National Cancer Institute (NCI) identifier: NCT00075387

Study Type: Interventional

Study Design: Supportive Care, Randomized, Active Control

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Edward A. Neuwelt, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site